Fig. 12.

Single low dose of IL-2 does not preferentially expand CD45RA⁻ HELIOS⁻TIGIT⁻ mTregs in vivo. (A,B) Data depict the variation (Mean +/− SEM) of the frequency of CD45RA⁻ HELIOS⁻TIGIT⁻ (A) or conventional CD45RA⁻ HELIOS⁺TIGIT⁺ mTregs (B), following IL-2 treatment in T1D patients receiving: (i) the lower IL-2 doses of 0.04–0.045×10⁶ U/ml (N = 2; depicted in black); or (ii) the higher IL-2 doses of 0.6–1.5 x 10⁶ U/ml (N = 6; depicted in red). Data were obtained from intracellular staining of cryopreserved PBMCs from eight selected T1D patients enrolled in the “Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes” (DILT1D). The DILT1D data from individuals prior to normalization as a group are available, however they cannot be anonymized sufficiently to be able to put into the public domain without risk of participant identification. Data are available on request, through the Cambridge University institutional repository (DOI link: https://doi.org/10.17863/CAM.832).